Note: We are no longer accepting Actos cases.
About the Lawsuit
Actos, manufactured by Takeda Pharmaceutical Co., was approved for use by the FDA in July of 1999. This medication, which contains the active ingredient pioglitazone hydrochloride, is a member of a class of medications known as thiazolidinediones and is used to treat type two diabetes. Since its introduction on the market Actos has been linked to numerous possible health risks.
The lawsuits allege:
- Actos causes bladder cancer.
- Takeda and Eli Lilly knew about the risk and withheld the information.
- The companies failed to provide adequate warnings.
Actos has been linked to liver disease, kidney failure, cardiovascular issues and bladder cancer.
Bladder cancer is among the most common types of cancer diagnosed in the U.S. An average of one in 42 people will be diagnosed with bladder cancer in their lifetime. It is usually detected early, but it has a very high recurrence rate. There are five types of bladder cancer differentiated by which type of bladder cells the cancer has affected. The common symptoms of bladder cancer include:
- Frequent or painful urination
- Blood in the urine
- Back Pain
- Pelvic pain
- Swelling in the legs
Since the link between Actos and bladder cancer became public knowledge, people from all over the country are turning to the legal system for compensation of their emotional, physical and financial damages. Thousands of lawsuits have been filed against Takeda Pharmaceutical Co. by individuals who suffered injuries after taking Actos.
These lawsuits allege that Takeda failed to warn the public and health care providers about the risks associated with their product and further that they concealed data linking their product to certain serious health concerns. The number of federal lawsuits filed is so large that several thousand federal lawsuits have been assigned to a multidistrict litigation (MDL) in the U.S. District Court for the Western District of Louisiana.
In a recent article on Bloomberg.com there is word that Takeda may make an offer of $2.2 billion dollars to settle over 8,000 pending Actos lawsuits. While no settlement deal has officially been reached, talks of a potential settlement of such magnitude is evidence that Takeda may be worried about what the outcome of litigating all these cases may be.
The evidence linking Actos to bladder cancer “is unusually strong and clear,” Paul J. Pennock, a New York-based lawyer representing former users of the drug, said in a telephone interview. He said his firm, Weitz & Luxemberg, represents 1,200 former Actos users and that total cases could reach 10,000, with the firm getting calls about it every day.
Over the years, numerous studies have shown evidence of a link between Actos and an increased risk of bladder cancer. A May 2011 study which utilized adverse event reports sent to the FDA over a five year period from 2004 to 2009 showed that one fifth of the bladder cancer reports from those taking a diabetes medicine were from patients taking Actos. The following month officials in France and Germany suspended sales of Actos in their respective countries.
The suspension came after a study by the French Medicines Agent found that the risk of bladder cancer among Actos users is 22 percent higher than those taking other diabetes medications. The same month that France and Germany suspended sales of Actos, the FDA issued a safety warning announcing a risk of bladder cancer associated with the use of Actos for more than a year. This safety announcement was most likely the trigger to a wave of lawsuits filed against Takeda.
Actos Heart Attacks
Under FDA recommendations, physicians began transitioning their patients to Actos from embattled diabetes competitor Avandia after it was revealed that the drug caused thousands of fatal heart attacks. Unfortunately, the research showed the same result for Actos. A side-by-side comparison study of 28,938 patients taking both drugs was published in August, 2010. The study found that after accounting for confounding effects such as age, gender and prior heart disease, about 4% of each group had a heart attack, heart failure or died.
- 121 patients on Actos suffered a heart attack, compared with 96 on Avandia.
- 243 on Actos suffered heart failure, compared with 265 on Avandia.
- 18 on Actos suffered both heart attack and heart failure, compared with 24 on Avandia.
- 217 on Actos died and 217 on Avandia.
Do I Have a Case?
Sanders Phillips Grossman is currently accepting cases from bladder cancer victims across the United States and Puerto Rico whom have used Actos as part of their diabetes treatment plan. If you or a loved one have been diagnosed with bladder cancer and have used Actos, you may be eligible for compensation. A successful outcome on your claim could entitle you to damages for medical expenses, wage loss, pain and suffering, loss of enjoyment of life, and loss of consortium.
WHAT WILL AN ATTORNEY COST ME?
We represent our clients on a contingency fee basis. This means that you pay no attorney fees until we win your claim. If we are unable to successfully resolve your claim, you are not obligated to pay attorneys’ fees.
About Sanders Phillips Grossman
Sanders Phillips Grossman has been holding pharmaceutical companies responsible for injuring individuals by their defective drugs and devices for over 30 years. Defective drugs are pharmaceuticals with side effects that potentially harm, injure, or kill the patient to the point that they outweigh the drug’s intended benefits. Defective devices, such as faulty prosthetics, implants, pacemakers or surgical instruments can harm patients when the product is defective in the manufacturing process, design or marketing strategy.
Pharmaceutical companies are some of the largest, wealthiest, and most influential corporate entities in the world. Sanders Phillips Grossman and its predecessors have recovered over one billion dollars for injured consumers. Our firm’s history in dealing with drug and medical device injury claims has allowed us to take leadership roles in many of the national defective drug and device litigations.
Nationally recognized as a leading plaintiff’s law firm, we handle cases in all 50 states and Puerto Rico.
Read more about our attorneys here.